1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K.

4892.T
Cyfuse Biomedical K.K.JP flagTokyo Stock Exchange
530.00
JPY
-18.00
- -
4.47BMarket Cap
Cyfuse Biomedical K.K.
4892.T
(Tokyo Stock Exchange)

Recent

price

530.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
19.18
1,415.07
140.38
7.82
6.76
- -
7.7
Revenue per Share
-45.97
285.52
-177.67
-75.42
-108.34
- -
-85.02
Basic EPS, GAAP
-41.05
322.75
-236.87
-74.47
-95.53
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-149.23
-1,644.11
-46.8
-89.94
-185.52
- -
-136.04
Book Value per Share
215.38
3,786.83
1,411.12
409.5
315.28
- -
370.31
Tangible Book Value per Share
7
1
3
8
8
- -
8
Basic Weighted Avg Shares
137
708
374
61
54
231
61
Sales/Revenue/Turnover
-270.68
9.96
-113.52
-1,141.24
-1,645.91
-358.52
-1,285.67
Operating Margin (%)
33
18
54
38
36
35
- -
Depreciation Expense
-330
143
-474
-589
-872
-764
-672
Net Income, GAAP
- -
1.39
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-239.66
20.18
-126.57
-964.15
-1,602.02
-330.67
-1,103.48
Profit Margin (%)
1,945
2,172
3,883
3,321
2,592
3,068
2,951
Working Capital
440
360
363
345
327
642
336
LT Debt
1,549
1,900
3,770
3,203
2,542
2,758
2,931
Total Equity
- -
3.04
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-37.3
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
568
468
468
LT Borrowings
345
340
336
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
5,940
5,792
5,840

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
3,987
3,683
3,529
Cash, Cash Equivalents & STI
3,874
3,556
3,385
Accounts Receivable, Net
17
8
4
Inventories
46
52
49
Total Current Liabilities
666
568
578
Payables & Accruals
- -
- -
- -
ST Debt
568
468
468
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.77%
8.47%
Free Cash Flow
- -
-129.21%
-24.28%
Net Income, GAAP
- -
-103.02%
-12.43%
Sales/Revenue/Turnover
- -
119.54%
324.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
7
- -
- -
54
2025
- -
- -
- -
- -
231
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-28.38
- -
- -
- -
-108.34
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Tibet Weixinkang Medicine Co., Ltd. (603676.SS)
Nectar Lifesciences Limited (NECLIFE.BO)
Morepen Laboratories Limited (MOREPENLAB.BO)
Qianhai Health Holdings Limited (0911.HK)
Yuhan Corporation (000105.KS)
Tsumura & Co. (4540.T)
Business
Cyfuse Biomedical K.K. (4892.T) develops, manufactures and sells regenerative medicine products and 3D bioprinting systems in Japan. The company offers Bio 3D Printers including regenova, a robotic system for fabricating 3D cellular structures from cell spheroids arranged in needle arrays; and S-PIKE, a next-generation printer for scaffold-free tissue engineering applicable to cartilage, bone, blood vessels, nerves and drug discovery models; alongside functional cellular devices as tools for pharmaceutical research and contract development of cell products. Founded in 2010 and headquartered in Minato-ku, Tokyo, with an additional office in Fukuoka, the firm targets healthcare providers, pharmaceutical companies and research institutions through its proprietary scaffold-free 3D printing platform. Recent developments include a 2025 joint announcement with PHC Corporation on innovative 3D cell product production technology for commercialization; business partnership with Marubeni Corporation for global expansion of S-PIKE; and sales alliance with Sysmex Corporation to market the printer; building on the 2023 strategic alliance with PHC to accelerate regenerative medicine pipelines.